More on the EpiPen and the FDA

The patent owner of the EpiPen is the target of our wrath over its price. However, as I noted in a previous post, there is much more to the story than greed. That includes the US regulatory process which enables such actions in the absence of competition. 

Consider this from a Wall Street Journal article September 1, 2016. 

Yet in Eu­rope, Epi­Pen com­petes with sev­eral de­vices at a frac­tion of its U.S. list price of $608.61 per pair. Den­mark’s ALK-Abello, which spe­cial­izes in al­lergy ther­a­pies, sells the Jext pen for $34 to $67 through­out Eu­rope, and is in­ter­ested in sell­ing it in the U.S. “Our de­ci­sion will be de­termined by what it takes to ob­tain FDA ap­proval,” says a spokesman.

This is just one example of our processes inhibiting competition. Many people hold European health care as a models up for us to follow; here is an example of how Europeans do things differently. 


What's your opinion on this post? Readers would like your point of view.

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s